INTI · Inhibitor Therapeutics, Inc.
$0.09
At close · Aug 27
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions and events raise substantial doubt about the Company's ability to continue as a going concern. ... Because management's plans have not yet been fully executed and are not within the Company's control, the implementation of such plans cannot be considered probable. As a result, the Company has concluded that management's plans do not currently alleviate substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$15.47M
Shares
173.79M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2021
Net Income
-$3.3M
+1.2%
FY2025
Diluted EPS
-$0.02
0%
FY2025
Operating Cash Flow
-$3.23M
+0.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| — | — | — | — | — | -$14.84K | $1058 | $14.54K | $14.03K | $17.87K | $21.99K | — | — | — | — | |
| $1.7M | $1.7M | $1.76M | $1.38M | $6150 | $4905 | $185.29K | $1.21M | $2.63M | $2.23M | $2.64M | $1.68M | $2.43M | $1.07M | — | |
| $1.67M | $1.73M | $1.9M | $2.02M | $651.78K | $320.49K | $873.7K | $1.54M | $1.93M | $2.89M | $4.38M | $2.27M | $1.51M | $817.32K | $560.67K | |
| $3.37M | $3.43M | $3.66M | $3.4M | $657.93K | $325.4K | $1.06M | $2.75M | $4.56M | $5.12M | $7.02M | $3.95M | $3.94M | $2M | $560.67K | |
| -$3.37M | -$3.43M | -$3.66M | -$3.4M | -$657.93K | -$325.4K | -$1.06M | -$2.75M | -$4.56M | -$5.12M | -$7.02M | -$3.95M | -$3.94M | -$2M | -$560.67K | |
| — | — | — | — | $23.23K | $14.84K | — | — | — | — | — | — | $37.48K | $1923 | — | |
| — | — | — | -$3.03M | $12.16M | -$298.63K | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | $55.11K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| -$3.31M | -$3.3M | -$3.34M | -$3.03M | $12.11M | -$298.63K | -$1.06M | -$2.73M | -$4.55M | -$5.1M | -$7M | -$3.95M | -$3.98M | -$1.84M | $186.37K | |
| — | — | — | -$3.03M | $11.92M | -$498.63K | — | — | — | — | — | — | — | — | — | |
| USD/shares | -$0.02 | -$0.02 | -$0.02 | -$0.02 | $0.03 | $0.00 | — | — | — | — | — | — | — | -$0.10 | $0.01 |
| USD/shares | -$0.02 | -$0.02 | -$0.02 | -$0.02 | $0.03 | $0.00 | — | — | — | — | — | — | — | -$0.10 | $0.01 |
| shares | — | 172.51M | 172.26M | 171.95M | 366.18M | 376.25M | 371.93M | 370.43M | 369.81M | 366.62M | 288.75M | 232.62M | 95.88M | 17.94M | 13.65M |
| shares | — | 172.51M | 172.26M | 171.95M | 366.18M | 376.25M | 371.93M | 370.43M | 369.81M | 366.62M | 288.75M | 232.62M | 95.88M | 17.94M | 13.65M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2020: $99.18K in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.36×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.91×
Peer medians compare against the 217 similar-size Biotechnology companies (of 514 listed).